2024
Racial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study
Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study. Cancer 2017, 123: 3754-3762. PMID: 28621841, PMCID: PMC6540984, DOI: 10.1002/cncr.30814.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaRisk of deathSupportive careEnd Results-Medicare databaseOlder adultsMedian OS timeOverall survival benefitCohort of patientsProportional hazards modelUse of HMAsMedian OSAgent therapySurvival benefitOS timeCMML patientsMyelomonocytic leukemiaHazards modelHMA treatmentPatientsTemporal improvementSecondary analysisPropensity scoreLimited evidenceSurvival changesApproval
2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabineDisease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes
Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes. Cancer 2016, 122: 1598-1607. PMID: 26970288, PMCID: PMC5509410, DOI: 10.1002/cncr.29945.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeEligible patientsHazard ratioMedicare beneficiariesMultivariate Cox proportional hazards modelEnd Results-Medicare databasePropensity score-matched groupsCox proportional hazards modelOverall study populationSubgroup of patientsConfidence intervalsCost-saving interventionEnd of studyProportional hazards modelElderly patientsOverall survivalDisease characteristicsMDS cohortPatient outcomesStudy populationInternational ClassificationWarrants additional researchHazards modelPatientsSurvival rate
2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Ma X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes & Control 2011, 22: 623-629. PMID: 21287258, PMCID: PMC3086405, DOI: 10.1007/s10552-011-9735-6.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesSurvival of patientsRisk of deathMyelodysplastic syndromeMDS survivalLifestyle factorsMultivariate Cox proportional hazards modelHigh-risk myelodysplastic syndromeCox proportional hazards modelLow-risk patientsProportional hazards modelInitial clinical encounterClinical characteristicsHazard ratioIndependent predictorsPrognostic roleMDS patientsCigarette smokingPoor survivalHematological malignanciesElevated riskHazards modelPatientsSmokingClinical encounters
2009
Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States
Wang R, Gross CP, Halene S, Ma X. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes & Control 2009, 20: 1369-1376. PMID: 19455395, PMCID: PMC2921772, DOI: 10.1007/s10552-009-9362-7.Peer-Reviewed Original ResearchConceptsNeighborhood socioeconomic statusMyelodysplastic syndromeSocioeconomic statusElderly patientsHazard ratioMultivariate Cox proportional hazards modelCox proportional hazards modelSurvival of patientsPopulation-based studyRisk of deathRisk of mortalityProportional hazards modelImpact of SESLow socioeconomic statusCensus tractsPrognostic roleMDS patientsIndependent determinantsRefractory anemiaHistological subtypesHazards modelPatientsSES statusTractS scoresComorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research 2009, 33: 1594-1598. PMID: 19324411, PMCID: PMC2749891, DOI: 10.1016/j.leukres.2009.02.005.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeHazard ratioComorbid conditionsMDS patientsCharlson indexMultivariate Cox proportional hazards modelPrognosis of MDSChronic obstructive pulmonary diseaseCox proportional hazards modelLarge population-based studyCongestive heart failureObstructive pulmonary diseaseRole of comorbiditiesMedian survival timePopulation-based studyProportional hazards modelMDS survivalHeart failurePulmonary diseaseIndependent determinantsShorter survivalLarge cohortSurvival timeHazards modelComorbidities